Edwards Lifesciences Corporation
New York Stock ExchangeRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Edwards Lifesciences Corporation is a medical technology company specializing in structural heart disease treatments, primarily manufacturing and marketing surgical heart valve repair and replacement devices, transcatheter heart valves, transcatheter mitral and tricuspid therapies, and hemodynamic monitoring systems. Its core products include the SAPIEN transcatheter heart valve line used in aortic stenosis treatments, the PASCAL transcatheter repair system for mitral and tricuspid valves, the Evoque transcatheter tricuspid valve replacement, and a portfolio of surgical heart valves and accessories. The company also provides advanced tissue technologies under the RESILIA platform and pressure and hemodynamic monitoring devices for critical care applications. Edwards operates globally with manufacturing facilities and commercial operations in the United States, Costa Rica, Dominican Republic, Puerto Rico, Singapore, and Ireland. Founded in 1958, it is headquartered in Irvine, California. Recent major company developments include Edwards' strategic expansion via acquisitions, notably JenaValve Technology and Endotronix, which it acquired for approximately $1.6 billion in 2024 to enhance its structural heart disease portfolio with emerging treatments for aortic regurgitation and heart failure monitoring. In mid-2024, Edwards completed the sale of its Critical Care product group to Becton, Dickinson and Company (BD) for $4.2 billion, reflecting a strategic focus shift to core structural heart innovations. The company continues to advance its product pipeline with upcoming FDA approvals, including the SAPIEN M3 transcatheter mitral valve system projected for early 2026 and the next-generation PASCAL system slated for late 2026. Edwards is also preparing to launch the TRIFORMIS surgical valve for the tricuspid position in the U.S. in the second half of 2026 and expects significant clinical trial milestones in 2026. Its financial outlook remains strong, with projected sales growth of 8-10% for 2026 and ongoing development in structural heart therapies and expanded treatment indications.
Edwards Lifesciences Corporation $EW Shares Acquired by Andra AP fonden
Edwards' Q2 Earnings on the Horizon: What's in the Cards?
Boston Common Asset Management LLC Has $12.52 Million Stock Position in Edwards Lifesciences Corporation $EW
Edwards Lifesciences Corporation $EW Shares Sold by Diversify Wealth Management LLC
Edwards Lifesciences to Host Earnings Conference Call on July 23, 2026
Did Edwards Lifesciences Corporation Insiders Breach their Fiduciary Duties to Shareholders?
Edwards' Structural Heart Leadership Demonstrated Through Expanding Body of Scientific Evidence at New York Valves
Pacific Defense Launches Dual-Enclave 100G Ethernet Switch for Secure Multi-Mission C5ISR and Electronic Warfare Systems
EW DCF Analysis: Intrinsic Value $51 vs Price $89
Edwards Lifesciences Stands Out As US Agency Eyes Broader Access For Heart Valve Device
Should You Continue to Hold EW Stock in Your Portfolio?
East West Announces $858,000 Non-Brokered Private Placement
Edwards Lifesciences Corp (EW) Stock Up 3.1% and Still Undervalued -- GF Score: 95/100
Is EW Overvalued? DCF Says Worth $51
Edwards Lifesciences Corporation (EW) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Is Edwards Lifesciences Corp (EW) a Bargain After 3.5% Drop? GF Value Says Undervalued
AI, Obesity Drugs, and Diagnostics Fuel Healthcare Growth
Edwards Lifesciences Announces Appointment of CFO
Ten-Year Pivotal Data Demonstrate Long-Term Durability of Edwards Lifesciences' Resilia Tissue
Artisan Global Opportunities Fund Q1 2026 Portfolio Activity